Zobrazeno 1 - 10
of 363
pro vyhledávání: '"Merola JF"'
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology, Vol Volume 17, Pp 539-545 (2024)
Joseph F Merola,1,* Ahmad Z Amin2,* 1Brigham and Women’s Hospital, Boston, Massachusetts, USA; 2Northwestern University Feinberg, School of Medicine, Chicago, Illinois, USA*These authors contributed equally to this workCorrespondence: D
Externí odkaz:
https://doaj.org/article/cfdb7467dbd2499f8476e6e7e1d581d6
Autor:
Aletaha D, Husni ME, Merola JF, Ranza R, Bertheussen H, Lippe R, Young PM, Cappelleri JC, Brown TM, Ervin C, Hsu MA, Fallon L
Publikováno v:
Patient Preference and Adherence, Vol Volume 14, Pp 949-961 (2020)
Daniel Aletaha,1 M Elaine Husni,2 Joseph F Merola,3 Roberto Ranza,4 Heidi Bertheussen,5 Ralph Lippe,6 Pamela M Young,7 Joseph C Cappelleri,8 T Michelle Brown,9 Claire Ervin,9 Ming-Ann Hsu,10 Lara Fallon11 1Division of Rheumatology, Department of Inte
Externí odkaz:
https://doaj.org/article/b31ee86e8134417691db402e15c60765
Autor:
Merola, JF, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gossec, L, Gottlieb, AB, Thaçi, D, Warren, RB, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J, Coates, LC
Publikováno v:
The Lancet, 401(10370), 38-48. Elsevier Limited
Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with placebo over 16 weeks in patients with active psoriatic arthritis and pre
Autor:
Ritchlin, CT, Coates, LC, McInnes, IB, Mease, PJ, Merola, JF, Tanaka, Y, Asahina, A, Gossec, L, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Landewé, R
Objectives: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ treatment has demonstrated superior efficacy versus placebo (PBO) at Week 16 in biologic disease‑modifying ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::0ae8f298a66cfb33a4fb1de689e01e8c
https://ora.ox.ac.uk/objects/uuid:24f30bf1-7136-47c4-8f1d-af2f12c9bbad
https://ora.ox.ac.uk/objects/uuid:24f30bf1-7136-47c4-8f1d-af2f12c9bbad
Autor:
Song, K, Eder, L, FitzGerald, O, Goel, N, Helliwell, PS, Katz, A, Merola, JF, Rosen, CF, Coates, L, Poddubnyy, D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::0239809e8b97935be27f82ae348bf63c
https://ora.ox.ac.uk/objects/uuid:bfbd48b7-e168-4270-b654-1a7364327365
https://ora.ox.ac.uk/objects/uuid:bfbd48b7-e168-4270-b654-1a7364327365
Autor:
Leung, Y-Y, Tillett, W, de Wit, M, Orbai, A-M, Coates, LC, FitzGerald, O, Helliwell, PS, Strand, V, Mease, P, Goel, N, Christensen, R, Merola, JF, Lindsay, C, Ogdie, A, Gossec, L, Gladman, DD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::d2ea35dfb7c75a9c914694d7fa84794e
https://ora.ox.ac.uk/objects/uuid:8140d0a2-c340-4be9-8f90-b05ec031ebb4
https://ora.ox.ac.uk/objects/uuid:8140d0a2-c340-4be9-8f90-b05ec031ebb4
Autor:
de Vlam, K, Mease, PJ, Bushmakin, AG, Fleischmann, R, Ogdie, A, Azevedo, VF, Merola, JF, Woolcott, J, Cappelleri, JC, Fallon, L, Taylor, PC
Publikováno v:
Rheumatology and Therapy. 9:1451-1464
Introduction:Pain is a multidimensional factor and core domain of psoriatic arthritis (PsA). This analysis aimed to quantify the role of potential inflammation-associated outcomes on pain reduction in patients with PsA receiving tofacitinib, using me
Autor:
Skougaard, M, Stisen, ZR, Jørgensen, TS, Egeberg, A, Hansen, RL, Perez-Chada, LM, Mogensen, M, Merola, JF, Gerwien, JG, Kristensen, LE
Publikováno v:
Scandinavian Journal of Rheumatology; May2023, Vol. 52 Issue 3, p259-267, 9p
Autor:
de Bruin-Weller, M, Merola, JF, Hong, CH, Baldrich, ES, Ettler, K, Sierka, D, Delevry, D, Chen, Z, Rossi, AB
Publikováno v:
Dermatology and Therapy
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Introduction: Atopic dermatitis (AD), a predominantly type 2 inflammatory skin disease, affects approximately 2-5% of adults, with a high burden of disease. In moderate-to-severe AD, lesions can be extensive and pruritus intense with patients experie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::1c90d2695f2e45122a086786b0dc49ad
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4238
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4238